- Home
- EML vs ALEC Comparison
EML vs ALEC Comparison
Compare EML & ALEC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EML
- ALEC
- Stock Information
- Founded
- EML 1858
- ALEC 2013
- Country
- EML United States
- ALEC United States
- Employees
- EML N/A
- ALEC N/A
- Industry
- EML Industrial Machinery/Components
- ALEC Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- EML Consumer Discretionary
- ALEC Health Care
- Exchange
- EML Nasdaq
- ALEC Nasdaq
- Market Cap
- EML 149.9M
- ALEC 124.0M
- IPO Year
- EML N/A
- ALEC 2019
- Fundamental
- Price
- EML $21.31
- ALEC $3.04
- Analyst Decision
- EML
- ALEC Buy
- Analyst Count
- EML 0
- ALEC 7
- Target Price
- EML N/A
- ALEC $4.50
- AVG Volume (30 Days)
- EML 9.2K
- ALEC 1.1M
- Earning Date
- EML 11-04-2025
- ALEC 11-05-2025
- Dividend Yield
- EML 2.06%
- ALEC N/A
- EPS Growth
- EML N/A
- ALEC N/A
- EPS
- EML N/A
- ALEC N/A
- Revenue
- EML $269,054,445.00
- ALEC $81,130,000.00
- Revenue This Year
- EML $1.56
- ALEC N/A
- Revenue Next Year
- EML $7.00
- ALEC $290.64
- P/E Ratio
- EML $11.92
- ALEC N/A
- Revenue Growth
- EML 1.30
- ALEC 46.77
- 52 Week Low
- EML $19.06
- ALEC $0.87
- 52 Week High
- EML $35.03
- ALEC $6.14
- Technical
- Relative Strength Index (RSI)
- EML 38.43
- ALEC 53.40
- Support Level
- EML $21.53
- ALEC $2.87
- Resistance Level
- EML $22.75
- ALEC $3.40
- Average True Range (ATR)
- EML 0.73
- ALEC 0.21
- MACD
- EML -0.16
- ALEC -0.03
- Stochastic Oscillator
- EML 9.64
- ALEC 44.74
About EML Eastern Company (The)
The Eastern Co manages industrial businesses that design, manufacture, and sell engineered solutions to industrial markets. The company manages the financial, operational, and strategic performance of its businesses to increase cash generation, operating earnings, and long-term shareholder value. It operates in the United States and Other Countries and generates the majority of its revenue from the United States.
About ALEC Alector Inc.
Alector Inc is a clinical-stage biopharmaceutical company. It is engaged in developing a novel therapeutic approach for the treatment of neurodegeneration. The firm is involved in developing therapies that are designed to simultaneously counteract pathologies by restoring healthy immune function to the brain. Its pipeline products include AL001, AL002, AL003, and AL101.